PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) ...

Colon cancer is a leading yet preventable cause of cancer deaths. Screening, especially colonoscopy, is crucial for early ...

Palisade Bio, Inc. (($PALI)) announced an update on their ongoing clinical study. Study Overview: Palisade Bio, Inc. has completed a Phase 1 ...

Colorectal cancer cases are increasing among adults under 50, with screening guidelines now recommending starting at age 45.

With colorectal cancer on the rise in people under 50, researchers at the University of Illinois Urbana-Champaign are looking at the colon's tiniest ...

Researchers at UC San Diego have identified a potential culprit behind rising cancer rates in millennials and Gen X.

The U.S. Food and Drug Administration announced Thursday it is launching "FDA PreCheck" in order to help construct drug ...

Palisade Bio’s locally-activated, terminal ileum and colon-targeted PDE4 B/D inhibitor, PALI-2108 receives Chinese patent: Carlsbad, California Monday, August 4, 2025, 16:00 Hrs ...

A University of California-San Diego study says older women who stand up more times a day have better heart health than their ...

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, ...

TUESDAY, August 5, 2025 (HealthDay News) — C. diff, which is short for Clostridioides difficile, is a type of bacteria that ...

Salt Lake City-based Intermountain Health has opened its first freestanding endoscopy center at Alta View Hospital in Sandy, Utah, with two more planned near Riverton Hospital and McKay-Dee Hospital, ...